Jerman - Jerman - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

ratiopharm gmbh (3087881) - clarithromycin - granulat zur herstellung einer suspension zum einnehmen - teil 1 - granulat zur herstellung einer suspension zum einnehmen; clarithromycin (23929) 0,25 gramm

Jerman - Jerman - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

ratiopharm gmbh (3087881) - clarithromycin - granulat zur herstellung einer suspension zum einnehmen - teil 1 - granulat zur herstellung einer suspension zum einnehmen; clarithromycin (23929) 0,125 gramm

Belgia - Belanda - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva pharma belgium sa-nv - clarithromycine 500 mg - filmomhulde tablet - 500 mg - clarithromycine 500 mg - clarithromycin

Belgia - Belanda - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva pharma belgium sa-nv - clarithromycine 250 mg - filmomhulde tablet - 250 mg - clarithromycine 250 mg - clarithromycin

Prancis - Prancis - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

accord healthcare france sas - clarithromycine 250 mg - comprimé - 250 mg - pour un comprimé > clarithromycine 250 mg - macrolides - clarithromycine accord 250 mg, comprimé pelliculé appartient à un groupe d’antibiotique de la famille des macrolides. les antibiotiques arrêtent la croissance des bactéries responsables de l’infection.clarithromycine accord 250 mg, comprimé pelliculé est utilisé dans le traitement des infections bactériennes suivantes, qui ont été préalablement diagnostiquées par votre médecin : infections thoraciques telles que bronchites et pneumonies communautaires, infections de la gorge et des sinus, infections cutanées et des tissus (impétigo, érysipèles, érythrasma), en association, en vue de l’éradication de helicobacter pylori en cas de maladie ulcéreuse gastro-duodénale (cette indication est restreinte à l’adulte seulement).clarithromycine accord est indiqué chez les adultes et les adolescents de plus de 12 ans..

Amerika Serikat - Inggris - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin 250 mg - clarithromycin tablets usp are indicated for the treatment of mild to moderate infections caused by susceptible isolates of the designated bacteria in the conditions as listed below: pharyngitis/tonsillitis due to streptococcus pyogenes (the usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. clarithromycin is generally effective in the eradication of s. pyogenes from the nasopharynx; however, data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present). acute maxillary sinusitis due to haemophilus influenzae , moraxella catarrhalis , or streptococcus pneumoniae . acute bacterial exacerbation of chronic bronchitis due to haemophilus influenzae , haemophilus parainfluenzae , moraxella catarrhalis , or streptococcus pneumoniae . community-acquired pneumonia due to haemophilus influenzae , mycoplasma pneum

Amerika Serikat - Inggris - NLM (National Library of Medicine)

actavis pharma, inc. - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin 500 mg - clarithromycin extended-release tablets are indicated in adults for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae, haemophilus parainfluenzae, moraxella catarrhalis, or streptococcus pneumoniae [see indications and usage (1.9)] . clarithromycin extended-release tablets (in adults) are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae, moraxella catarrhalis, or streptococcus pneumoniae [see indications and usage (1.9)] . clarithromycin extended-release tablets are indicated [see indications and usage (1.9)] for the treatment of mild to moderate infections caused by susceptible isolates due to: - haemophilus influenzae (in adults) - haemophilus parainfluenzae (in adults) - moraxella catarrhalis (in adults) - mycoplasma pneumoniae, streptococcus pneumoniae , chlamydophila pneumoniae (in adults) clarithromycin extended-release tablets are indicated only for acute maxillary

Amerika Serikat - Inggris - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin 500 mg - clarithromycin extended-release tablets are indicated in adults for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae, haemophilus parainfluenzae, moraxella catarrhalis, or streptococcus pneumoniae [see indications and usage ( 1.9)] . clarithromycin extended-release tablets (in adults) are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae, moraxella catarrhalis, or streptococcus pneumoniae [see indications and usage ( 1.9)] . clarithromycin extended-release tablets are indicated [see indications and usage ( 1.9)] for the treatment of mild to moderate infections caused by susceptible isolates due to: - haemophilus influenzae (in adults) - haemophilus parainfluenzae (in adults) - moraxella catarrhalis (in adult

Amerika Serikat - Inggris - NLM (National Library of Medicine)

allied pharma inc - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin 250 mg - clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible isolates of the designated bacteria in the conditions as listed below: adults pharyngitis/tonsillitis due to streptococcus pyogenes (the usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. clarithromycin is generally effective in the eradication of s. pyogenes from the nasopharynx; however, data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present). acute maxillary sinusitis due to haemophilus influenzae , moraxella catarrhalis, or streptococcus pneumoniae . acute bacterial exacerbation of chronic bronchitis due to haemophilus influenzae , haemophilus parainfluenzae, moraxella catarrhalis, or streptococcus pneumoniae. community-acquired pneumonia due to haemophilus influenzae , mycop

Amerika Serikat - Inggris - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin 500 mg - clarithromycin tablets are indicated in adults for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae , haemophilus parainfluenzae , moraxella catarrhalis , or streptococcus pneumoniae [see indications and usage (1.9)] . clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae , moraxella catarrhalis , or streptococcus pneumoniae [see indications and usage (1.9)] . clarithromycin tablets are indicated [see indications and usage (1.9)] for the treatment of mild to moderate infections caused by susceptible isolates due to: clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to streptococcus pyogenes as an alternative in individuals who cannot use first line therapy. clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to staphylococ